Ropeginterferon alfa-2b for chronic myelomonocytic leukemia and related overlap blood cancers

Trial details

Who runs it

Jonsson Comprehensive Cancer Center

Trial code

NCT07468916

Record updated

5 November 2026

Original description

This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and chronic myelomonocytic leukemia. Ropeginterferon alfa-2b is a form of interferon. Interferons are a type of signaling protein normally produced by the body as part of the immune response. Interferons interfere with the division of cancer cells and can slow cancer cell growth. Ropeginterferon alfa-2b is a long-acting form of a type of interferon called interferon alfa-2b. In the body, ropeginterferon alfa-2b causes the production of proteins that modulate the immune system and have anticancer effects.Read full original descriptionShow less

Ropeginterferon Alfa-2b for MDS/MPN Overlap Syndromes, Including CMML and MDS/MPN-RS-T

This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and chronic myelomonocytic leukemia. Ropeginterferon alfa-2b is a form of interferon. Interferons are a type of signaling protein normally produced by the body as part of the immune response. Interferons interfere with the division of cancer cells and can slow cancer cell growth. Ropeginterferon alfa-2b is a long-acting form of a type of interferon called interferon alfa-2b. In the body, ropeginterferon alfa-2b causes the production of proteins that modulate the immune system and have anticancer effects.

Inclusion: Male or female ≥ 18 years of age at time of consent; Documentation of a diagnosis of MDS/MPN overlap syndrome based on World Health Organization (WHO) 2022 classification, including CMML, MDS/MPN with neutrophilia, myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), or MDS/MPN, not otherwise specified, by local pathology review, and deemed to potentially benefit from study participation by the investigator; Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study; Blast =< 10% by marrow immunohistochemistry stain; Platelet count of > 50,000/uL; Absolute neutrophils count (ANC) of > 1000/uL; Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2; Serum creatinine =< 2.5 mg/dL; Serum direct bilirubin < 2.0 mg/dL; Serum transaminase < 2.5 times the upper limit of the normal range (ULN) or < 5 times ULN if the transaminase elevation was deemed related to the MDS/MPN.

Exclusion: Prior therapy with interferon or pegylated interferon product, or azacitidine; Other standard (including erythropoietin-stimulating agents [ESA] or luspatercept) or experimental therapy for MDS/MPN within 28 days of starting study therapy with the exception of hydroxyurea, which is allowed to continue up to 28 days after cycle 1 day 1 (C1D1) while on protocol; History of or current clinically relevant depression or anxiety per investigator's judgement. Previous suicidal ideation or attempts are not allowed to participate in interferon (IFN) therapy; History of any malignancy within 5 years (except adequately treated non-melanoma skin cancer, prostate cancer status post resection with an undetectable prostate-specific antigen [PSA], curative treated in-situ cancer of the cervix, ductal carcinoma in situ [DCIS] of the breast, stage 1 grade 1 endometrial carcinoma, or other solid tumors including lymphomas curatively treated with no evidence of disease for ≥ 1 year prior to study); Active abuse of alcohol and/or illicit drugs; Clinically significant autoimmune disease by investigator assessment, regardless if the autoimmune phenomena is related to MDS/MPN overlap syndrome; Evidence of severe retinopathy or clinically relevant ophthalmological disorder; History of organ transplant; Active uncontrolled infection with clinical symptoms, e.g., presence of bacteria, fungal, human immunodeficiency virus (HIV), hepatitis B or C; Active uncontrolled thromboembolic complications or hemorrhage; Uncontrolled active clinically significant illness that, in the investigator's opinion, may affect the patient's participation in this study; Spleen overtly enlarged by physical exam (eg. greater than 5 fingerbreadth below costal margin); Pregnant or breastfeeding women.

ClinicalTrials.gov NCT07468916